Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Net Cash Flow (2017 - 2025)

Puma Biotechnology's Net Cash Flow history spans 9 years, with the latest figure at -$23.9 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 1322.34% year-over-year to -$23.9 million; the TTM value through Dec 2025 reached -$39.6 million, down 157.62%, while the annual FY2025 figure was -$39.6 million, 157.62% down from the prior year.
  • Net Cash Flow reached -$23.9 million in Q4 2025 per PBYI's latest filing, down from -$1.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $25.2 million in Q3 2022 to a low of -$25.9 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$3.3 million, with a median of -$3.8 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: plummeted 3078.04% in 2021, then soared 229.9% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$816000.0 in 2021, then plummeted by 115.56% to -$1.8 million in 2022, then skyrocketed by 229.9% to $2.3 million in 2023, then decreased by 14.4% to $2.0 million in 2024, then plummeted by 1322.34% to -$23.9 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Net Cash Flow are -$23.9 million (Q4 2025), -$1.1 million (Q3 2025), and -$8.4 million (Q2 2025).